Pixium Vision announces the launch of a process to find buyers
October 18 2023 - 1:40PM
Pixium Vision announces the launch of a
process to find buyers
Paris, France, October 18, 2023
- 19:30 (CET ) - Pixium Vision SA (Euronext Growth Paris -
FR001400JX97; Mnemo: ALPIX) (the "Company"), a
bioelectronics company developing innovative vision systems to
enable patients who have lost their sight to live more independent
lives, announces that a tender process (appel d’offres) for the
purpose of finding buyers to acquire the Company's business will be
published tomorrow.
Having been unable to find financial investors
within the restricted timeframe and in line with the Company's
needs, a safeguard plan is no more an option. As a result, the
Company will be requesting the conversion of safeguard proceedings
(procédure de sauvegarde) into receivership (redressement
judiciaire).
In this context, the deadline for submission of
offers has been set by the court-appointed administrators to
November 20, 2023 at 12:00 p.m. (noon).
Interested candidates are invited to contact the
court-appointed administrators, SCP Abitbol & Rousselet,
represented by Joanna Rousselet, and Selarl FHB, represented by
Hélène Bourbouloux.
Access to an electronic data room will be
granted once the candidate has signed a confidentiality agreement
and submitted a brief presentation of interest.
The market will be regularly informed of
developments in the procedure and, more generally, of the Company's
financial situation.
About Pixium Vision
Pixium Vision is creating a
world of bionic vision for those who have lost their sight,
enabling them to regain visual perception and greater autonomy.
Pixium Vision’s bionic vision systems are associated with a
surgical intervention and a rehabilitation period. Prima System
sub-retinal miniature photovoltaic wireless implant is in clinical
testing for patients who have lost their sight due to outer retinal
degeneration, initially for atrophic dry age-related macular
degeneration (dry AMD). Pixium Vision collaborates closely with
academic and research partners, including some of the most
prestigious vision research institutions in the world, such as
Stanford University in California, Institut de la Vision in Paris,
Moorfields Eye Hospital in London, Institute of Ocular Microsurgery
(IMO) in Barcelona, University hospital in Bonn, and UPMC in
Pittsburgh, PA. The Company is EN ISO 13485 certified and qualifies
as “Entreprise Innovante” by Bpifrance.
Forward-Looking Statements. This press release
contains certain forward-looking statements. Although the Company
believes its expectations are based on reasonable assumptions,
these forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. For a discussion of risks and
uncertainties which could cause the Company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors (“Facteurs de Risques”) section of the Company’s
2022 Annual Financial Report and other documents the Company files
with the AMF, which is available on the AMF website (www.amf-
france.org) or on the Company’s website.
For more information:
http://www.pixium-vision.com/fr
Follow us on @PixiumVision;
www.facebook.com/pixiumvision
www.linkedin.com/company/pixium-vision
Contacts
Investor
RelationsPixium VisionOffer NonhoffChief
Financial Officerinvestors@pixium-vision.com |
Media
Relations Rose Piquante ConsultingSophie
BaumontSophie.baumont@rosepiquante-consulting.com+33 6 27 74 74
49 |
- PR - search for buyers launch - 17.10.23 EN
Pixium Vision (EU:ALPIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Pixium Vision (EU:ALPIX)
Historical Stock Chart
From Jul 2023 to Jul 2024